If you’re on a budget, yet in a risk-tolerant mood, it’s worth taking a look at penny stocks – companies whose shares sell …
Mizuho’s Difei Yang approaches the biotech player as a new bull, angling for a whopping 204% in return potential for MRNS shares.
Investors are cheering in response to positive mid-stage clinical trial results in CDKL5 disorder.
Yesterday, Marinus Pharmaceuticals Inc (NASDAQ:MRNS) announced more complete data from the exploratory Phase II study in 11 children with uncontrolled seizures due to …
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) shareholders are having a rough day as the company’s stock is down by 25%, following top-line results from its Phase 2 …
TESARO Inc (NASDAQ:TSRO) and Marinus Pharmaceuticals Inc (NASDAQ:MRNS) both made headlines this week as the biotech companies released data on pipeline drugs. While …
Amid drug trials and pipeline updates, analysts remain bullish on both Galena Biopharma Inc (NASDAQ:GALE) and Marinus Pharmaceuticals Inc (NASDAQ:MRNS). Analysts dive into …
KemPharm Inc KemPharm Inc (NASDAQ:KMPH) shares are falling over 25% after the FDA issued a complete response letter (CRL) to the company for Apadaz, an …
Marinus Pharmaceuticals Inc Monday turned out to be a nightmare for shareholders of Marinus Pharmaceuticals Inc (NASDAQ:MRNS), as the stock price tumbled 70% following the news …
